Diagnosis and Treatment of Neuroendocrine Tumors

Diagnostic Approach

The diagnosis of neuroendocrine tumors requires histopathological confirmation with specific markers (chromogranin A, synaptophysin, Ki-67), followed by a multimodal imaging approach including somatostatin receptor imaging alongside conventional CT and MRI, as recommended by the European Neuroendocrine Tumor Society 1, 2
Histopathological confirmation is mandatory in all cases, typically obtained through surgical, endoscopic, or ultrasound-guided biopsies, with a high level of evidence (Level 1) 1
Essential immunohistochemical markers include chromogranin A 3, synaptophysin 1, and Ki-67 proliferation index (required for grading) 1, 2
Classification according to WHO (2010) criteria includes NET G1: Ki-67 ≤2% 1, NET G2: Ki-67 3%-20% 1, and NEC G3: Ki-67 >20% 1

Baseline tests should include serum chromogranin A (general marker for most NETs) 3 and urinary 5-hydroxyindoleacetic acid (5-HIAA) for carcinoid tumors 1
For poorly differentiated G3 tumors, neuron-specific enolase (NSE) is a valuable alternative marker 1, 2

A multimodal approach is essential for detecting primary tumors and metastases 1
Standard imaging includes CT and MRI for anatomical localization and staging 1, 2
Somatostatin receptor imaging (Octreoscan or PET/CT using 68Ga-DOTA-peptides) is crucial for detection of NETs expressing somatostatin receptors 1, 2

Resection of locoregional disease is recommended, particularly for small intestinal NETs (carcinoids), with a moderate level of evidence (Level 2) 2
Somatostatin analog therapy is first-line for small intestinal NET G1/G2 2, 3
Targeted therapies, such as everolimus and sunitinib, are FDA-approved for pancreatic NETs based on phase III randomized trials, with a high level of evidence (Level 1) 2

For pancreatic NETs, temozolomide alone or in combination with capecitabine shows promising results (70% response rate) 2, 3
For poorly differentiated NECs (G3), cisplatin-etoposide is standard therapy (42-67% response rate) 2

Regular follow-up should include biochemical markers (chromogranin A or NSE if chromogranin A is not elevated) 2
Conventional imaging (CT/MRI) every 3-6 months for NET G1/G2 and every 2-3 months for NEC G3 2
Somatostatin receptor imaging is recommended after 18-24 months if somatostatin receptor 2a expression is confirmed 2

Relying solely on conventional imaging without somatostatin receptor imaging may miss NETs, with a low level of evidence (Level 3) 1
Failure to obtain Ki-67 index leads to improper grading and inappropriate treatment selection, with a moderate level of evidence (Level 2) 1

The National Comprehensive Cancer Network recommends that for small peripheral tumors, even when surgery is performed, enucleation or local excision is preferred over major resection to minimize morbidity 4, 5

The National Comprehensive Cancer Network suggests that less frequent surveillance may be appropriate for low-risk tumors such as well-differentiated stage I pancreatic NETs 4, 5
The European Society for Medical Oncology recommends that MRI is preferred for pancreatic imaging due to superior soft tissue characterization and lack of radiation exposure 6
The European Society for Medical Oncology suggests that baseline chromogranin A should be obtained and monitored during surveillance 7, 8

The National Comprehensive Cancer Network recommends that surgery should be considered during surveillance if tumor growth ≥5 mm/year develops 9
The National Comprehensive Cancer Network suggests that surgery should be considered during surveillance if development of symptoms related to mass effect or hormone secretion occurs 4
The National Comprehensive Cancer Network recommends that surgery should be considered during surveillance if increase in tumor size to ≥2 cm occurs 4, 5
The European Society for Medical Oncology suggests that surgery should be considered during surveillance if evidence of malignant features on imaging (enhancing mural nodules, lymphadenopathy) is found 9

The National Comprehensive Cancer Network recommends that tumors >2 cm require resection with negative margins and regional lymph node dissection 4, 5
The European Society for Medical Oncology suggests that any tumor with malignant-appearing features on imaging should be considered for surgery 4
The National Comprehensive Cancer Network recommends that functional tumors causing symptoms require surgical resection regardless of size due to symptomatic burden 4, 8